#SFHS2611954AFrance Adds Afinitor and Cotellic Presentations to the Reimbursable Medicines List
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The order adds two pharmaceutical products to France’s list of medicines reimbursed by social health insurance: Afinitor 10 mg and Cotellic 20 mg, both marketed by Abacus Medicine. For Afinitor, reimbursement is limited to specific cancer treatments, including advanced kidney cancer, certain pancreatic, gastrointestinal or lung neuroendocrine tumors, and a defined form of advanced breast cancer.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds Afinitor 10 mg to the reimbursable medicines list for specified cancer indications.
- Adds Cotellic 20 mg to the reimbursable medicines list for the indication covered by its marketing authorization at publication.
- Removes patient co-payment for the listed products under the applicable social security rule.
Obligations
What this law requires
French social health insurance must include AFINITOR 10 mg (everolimus), CIP 34009 495 018 9 2, marketed by Abacus Medicine, on the list of pharmaceutical specialties reimbursable to insured persons, with the insured person’s participation removed under Article R. 160-8 of the Social Security Code.
Reimbursement for AFINITOR 10 mg must be limited to the listed therapeutic indications, including advanced kidney cancer after progression during or after anti-VEGF targeted therapy; unresectable or metastatic pancreatic neuroendocrine tumors with disease progression in adults; specified advanced hormone receptor-positive HER2/neu-negative breast cancer in postmenopausal women in association with exemestane; and unresectable or metastatic well-differentiated gastrointestinal or lung neuroendocrine tumors in progression in adults.
French social health insurance must include COTELLIC 20 mg (cobimetinib), CIP 34009 495 019 5 3, marketed by Abacus Medicine, on the list of pharmaceutical specialties reimbursable to insured persons, with the insured person’s participation removed under Article R. 160-8 of the Social Security Code.
Reimbursement for COTELLIC 20 mg must be limited to the therapeutic indication appearing in its marketing authorization on the date this order is published.